SLC5A2 and cardiac hypertrophy: Experimental data indicate that finerenone attenuates inflammation, fibrosis, myocardial hypertrophy, and adverse remodeling, while proteomic and translational analyses suggest biological complementarity with sodium-glucose cotransporter 2 inhibitors.